Thursday, May 16, 2024 2:49:56 PM
May 16 2024 - 8:05AM
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.
“One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of Guardant Health. “The data we will share at DDW underscores the important role that our Shield blood test can have in both improving screening rates and in detecting more colorectal cancer at an early stage, when it is most treatable. We look forward to sharing this important data at DDW.”
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Recent GH News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:25:31 PM
- Guardant Health Named to TIME100 Most Influential Companies • Business Wire • 05/31/2024 12:05:00 PM
- Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening • Business Wire • 05/30/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 11:01:00 AM
- FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option • Business Wire • 05/23/2024 11:03:00 PM
- Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening • Business Wire • 05/23/2024 11:05:00 AM
- Guardant Health to Participate in Upcoming Investor Conferences • Business Wire • 05/22/2024 08:05:00 PM
- Guardant Health erhält EU-IVDR-Zertifizierung für Flüssigbiopsie Guardant360® CDx zur Erstellung von Tumormutationsprofilen für alle soliden Krebsarten und therapiebegleitende Diagnostika-Indikationen • Business Wire • 05/21/2024 12:44:00 PM
- Guardant Health reçoit la certification IVDR de l’UE pour la biopsie liquide Guardant360® CDx destinée au profilage des mutations tumorales dans tous les cancers solides et les indications de diagnostic compagnon • Business Wire • 05/21/2024 12:44:00 PM
- Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications • Business Wire • 05/21/2024 12:05:00 PM
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/17/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:17:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:12:12 PM
- Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week • Business Wire • 05/16/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:59:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:11:54 PM
- Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance • Business Wire • 05/09/2024 08:05:00 PM
- Guardant Health to Participate in Upcoming Investor Conferences • Business Wire • 05/07/2024 08:05:00 PM
- Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone • Business Wire • 05/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 09:06:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 09:05:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 09:03:39 PM
- FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23 • Business Wire • 04/22/2024 12:52:00 PM
- Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 04/18/2024 08:05:00 PM
- Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting • Business Wire • 04/03/2024 12:05:00 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM